%0 Journal Article
%A Lodde, Georg C
%A Hassel, Jessica
%A Wulfken, Lena M
%A Meier, Friedegund
%A Mohr, Peter
%A Kähler, Katharina
%A Hauschild, Axel
%A Schilling, Bastian
%A Loquai, Carmen
%A Berking, Carola
%A Hüning, Svea
%A Eckardt, Julia
%A Gutzmer, Ralf
%A Reinhardt, Lydia
%A Glutsch, Valerie
%A Nikfarjam, Ulrike
%A Erdmann, Michael
%A Beckmann, Catharina L
%A Stang, Andreas
%A Kowall, Bernd
%A Galetzka, Wolfgang
%A Roesch, Alexander
%A Ugurel, Selma
%A Zimmer, Lisa
%A Schadendorf, Dirk
%A Forschner, Andrea
%A Livingstone, Elisabeth
%T Adjuvant treatment and outcome of stage III melanoma patients: Results of a multicenter real-world German Dermatologic Cooperative Oncology Group (DeCOG) study.
%J European journal of cancer
%V 191
%@ 0014-2964
%C Amsterdam [u.a.]
%I Elsevier
%M DKFZ-2023-01494
%P 112957
%D 2023
%X Clinical trials demonstrated significantly improved recurrence-free survival (RFS) of melanoma patients receiving adjuvant treatment. As data from controlled trials are based on selected populations, we investigated adjuvantly treated stage III melanoma patients under real-world conditions.In a prior multicenter cohort study, stage III-IV melanoma patients were analysed for their choice of adjuvant therapy. In this follow-up study, we examined RFS, overall and melanoma-specific survival (MSS) and response to the subsequent treatment of 589 stage III patients (232 BRAF-mutated) receiving adjuvant PD-1 inhibitors (PD1; n = 479) or targeted therapy (TT; n = 110).The median follow-up of the total cohort was 25.7 months. The main reason for premature discontinuation of adjuvant therapy was disease progression in PD1- (28.8
%K Adjuvant treatment (Other)
%K BRAF (Other)
%K Immunotherapy (Other)
%K Melanoma (Other)
%K PD1 (Other)
%K Real-world (Other)
%K Targeted therapy (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:37487400
%R 10.1016/j.ejca.2023.112957
%U https://inrepo02.dkfz.de/record/277779